Innovative Medicines Canada – Private Drug Plan Cost Drivers Report – Advisory Group

Chris was invited to review and comment on the new IMC Cost Drivers Analysis of Private Drug Plans in Canada (2016-2019) with a handful of successful benefit consultants, in a series of virtual meetings.  The meeting was intended to get our input on the new data and to answer some focused questions on key findings and topics.

Insights

More Related Articles

The Benefits Alliance welcomes Human Capital Benefits as a Member FIrm

Human Capital Benefits Benchmarking Tool – Coming Soon

Canadian Leadership Council on Drug Plan Partnerships